Establishment of novel therapy with hydrogen gas inhalation for traumatic brain injury

• Project/Area Number: 15K10982
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Emergency medicine
• Research Institution: Yamaguchi University
• Principal Investigator: FUJITA Motoki 山口大学, 大学院医学系研究科, 助教 (50380001)
• Co-Investigator(Kenkyū-buntansha): 宮内 崇 山口大学, 医学部附属病院, 助教 (40380000) ; 小田 泰崇 山口大学, 大学院医学系研究科, 准教授 (40397998)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Project Status: Completed (Fiscal Year 2017)
• Budget Amount: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000); Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000); Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000); Fiscal Year 2015: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
• Keywords: 頭部外傷 / 水素ガス / 軸索損傷 / オリゴデンドロサイト / HMGB1 / 水素吸入 / 水素

Outline of Final Research Achievements

In the present study, we revealed that oligodendrocytic apoptosis occurred in corpus callosum after severe traumatic brain injury, and that hydrogen gas inhalation therapy which could scavenge toxic free radicals suppressed axonal injury in corpus callosum and oligodendrocytic apoptosis. Further, hydrogen gas inhalation therapy combined with glycyrrhizin administration which could suppress HMGB1 revealed more suppression of axonal injury and oligodendrocytic apoptosis. The combination therapy including hydrogen gas inhalation and HMGB1 suppression might be novel therapy for severe traumatic brain injury.